CVS Caremark ® Mail Service Pharmacy and Aetna ® are both members of the CVS Health ® family of organizations. ** CVS Caremark ® Mail Service is a component of the CVS Health ® family of companies. Both CVS Specialty ® and Aetna are considered to be subsidiaries of the CVS Health family of organizations. We take protecting your privacy very seriously.
What is a mail order pharmacy?
What sets conventional prescriptions apart from those that may be obtained over the mail? – For the more conventional method of pickup, a healthcare provider will often place a prescription order over the phone with a neighborhood walk-in pharmacy (or you bring in the prescription paper).
After that, the prescription is filled by a pharmacist, who then checks it out with your insurance company before handing you the drug. When you get your prescription over the mail, a medical expert will submit it to a mail-order pharmacy, which will typically coordinate its efforts with your insurance provider and the pharmacy benefit manager for that provider (PBM).
The mail-order pharmacy fills your prescription, submits it for reimbursement to your insurance company, and then sends the drug to your home address. The co-pays are different for typical walk-in pharmacies as opposed to mail-order pharmacies. When determining whether to go with standard prescriptions or mail-order medicines, you should also keep in mind that the co-pays you are responsible for will be determined by your particular insurance policy.
What insulin is covered by Aetna?
| Status | Drug |
|---|---|
| P | Humulin® R (regular insulin, human) |
| P | Lantus® (insulin glargine) |
| P | Levemir® (insulin detemir) |
| P | Novolog® (insulin aspart) |
What is the difference between CVS Pharmacy and CVS Caremark?
CVS Caremark has announced that it would be changing its corporate name to CVS Health in order to better reflect the company’s expanded commitment to health care. CVS Health is at the vanguard of the rapidly evolving health care market, and the company possesses the knowledge to develop the innovations that will shape the future of health.
Ahead of schedule, the company has stopped selling cigarettes and has begun a thorough and highly individualized effort to encourage people to quit smoking. CVS Health has been praised by the Campaign for Tobacco-Free Kids for setting a “strong example,” and the organization is urging other shops with pharmacies to refrain from selling tobacco products.
WOONSOCKET, R.I. , September 3, 2014 — Today, CVS Caremark Corporation (NYSE: CVS) made the announcement that it would be changing its corporate name to CVS Health. This change will represent the company’s expanded commitment to health care as well as its experience in generating innovations that are necessary to define the future of health.
The President and Chief Executive Officer of CVS Health, Larry J. Merlo, stated that “for our patients and consumers, health is important,” and that the company is working to change the way that health care is delivered in order to increase access, decrease prices, and enhance quality. “As a pharmacy innovation firm at the vanguard of a changing health care landscape, we are offering ground-breaking goods and services.
These range from advising on prescriptions to assisting with the management of chronic and speciality disorders.” CVS Health consists of the company’s retail business, which will still be referred to as CVS/pharmacy; its pharmacy benefit management business, which is known as CVS/caremark; its walk-in medical clinics, which are known as CVS/minuteclinic; and its expanding specialty pharmacy services, which are known as CVS/specialty.
- CVS Health makes it possible for individuals, businesses, and communities to better manage their health in ways that are both more affordable and more effective.
- The company has 7,700 retail pharmacies, 900 walk-in medical clinics, a leading pharmacy benefits manager with nearly 65 million plan members, and is expanding its specialty pharmacy services.
According to Merlo, “CVS Health impacts the lives of more than 100 million people annually by playing an active and supporting role in each person’s individual health experience and in the wider health care ecosystem.” “Consumers are increasingly taking charge of their own health,” and “through our 26,000 pharmacists and nurse practitioners, we are supporting consumers on their journey to better health.” [Citation needed] “Consumers are increasingly taking responsibility of their own health.” CVS Health offers a variety of initiatives to assist individuals in the management of chronic diseases and links patients with pharmacists who provide assistance in maintaining adherence to the drugs recommended to them.
- These initiatives are being supplemented with digital capabilities, which are giving clients a comprehensive view of their prescriptions.
- Patients are given more options and more convenience thanks to CVS Health’s Specialty Connect and Maintenance Choice programs, which combine the capabilities of the company’s retail and mail-order pharmacies.
Through CVS/pharmacy and CVS/minuteclinic, CVS Health is forming strategic agreements with physicians and health plans in order to provide clinical assistance, medication counseling, chronic disease monitoring, and wellness initiatives for their members.
- As a further indication of its dedication to health, CVS Health also announced that tobacco sales will be discontinued at all CVS and drugstore locations as of September 3, nearly a month earlier than the date that had been scheduled previously, which was October 1.
- CVS/pharmacy is the first and only national drugstore chain to take this action in favor of the health and well-being of its patients and customers.
The firm made the announcement in February that it will discontinue the sale of cigarettes and other tobacco products at its CVS/pharmacy shops. “Today is the last day that cigarettes and other tobacco products can be purchased at CVS pharmacies; this change is being made in conjunction with the launch of CVS Health.
- We have the ability to make a positive impact on the health of all Americans if we forbid the sale of tobacco products and cigarettes at our retail establishments “Merlo remarked.
- “The sale of cigarettes at a retail pharmacy clashes with the goal of the health care services offered there,” noted Troyen A.
Brennan, M.D., M.P.H., Chief Medical Officer, CVS Health. “The aim of the health care services delivered there is to promote better health.” Even more importantly, there is growing research that suggests removing tobacco goods from businesses that also have pharmacies would lead to considerably reduced rates of smoking, which will have ramifications for decreasing the number of fatalities caused by tobacco use.
The findings of a recent study conducted by CVS Health and published in a blog post by Health Affairs demonstrate that the implementation of policies to prohibit the sale of tobacco products at retailers in San Francisco and Boston that also operate pharmacies was associated with a decrease of up to 13.3 percent in the number of customers who purchased tobacco products.
“Today should mark a call to action by all merchants involved in health care,” said Matthew L. Myers, President of the Campaign for Tobacco-Free Kids (CTFK), which advocates for the elimination of tobacco use among children. “We strongly encourage other businesses that also include pharmacies to stop selling tobacco products and learn from the tremendous example established by CVS/pharmacy.” In addition to eliminating cigarettes and other tobacco products from sale, CVS Health has launched a comprehensive and one-of-a-kind smoking cessation program with the goal of assisting millions of cigarette smokers in the United States to ditch the habit.
- “Quitting smoking is one of the most important things you can do to improve your health and protect the health of your family, but quitting is not easy,” said Helena Foulkes, President of CVS/pharmacy.
- “Quitting smoking is one of the most important things you can do to improve your health and protect the health of your family.” The CVS Health smoking cessation program was developed with input from national experts.
It combines the efforts of CVS/pharmacy, CVS/minuteclinic, and CVS/caremark to help smokers quit, and it includes four essential components: an assessment of the smoker’s readiness to quit, education to provide smokers with the information and tools they need to quit, medication support to help curb the desire to use tobacco, and coaching to help individuals stay motivated and prevent relapses.
“We realized as a result of our announcement in February that practically everyone has a tobacco story and was anxious to tell it,” Foulkes stated. “We were excited to hear these stories.” “Therefore, today we are beginning a social campaign under the hashtag #OneGoodReason, in which we are urging everyone to share their own accounts of how smoking and the use of tobacco has impacted their lives.
Sharing these experiences in the hopes of igniting a movement that will lead to substantial and long-lasting changes in the health of people all throughout the United States is our primary objective.” Merlo came to the conclusion that “today, as CVS Health, we are tobacco-free; we are reinventing pharmacy; and we are taking our position among leaders in the health care community.” About CVS Health CVS Health is a pharmacy innovation firm that assists individuals in achieving their health goals through a variety of services.
- People, businesses, and communities are able to manage their health in more affordable and effective ways thanks to our 7,700 retail pharmacies, 900 walk-in medical clinics, a leading pharmacy benefits manager with nearly 65 million plan members, and expanding specialty pharmacy services.
- These are just some of the ways we do this.
This innovative and integrated paradigm improves access to high-quality treatment while simultaneously lowering overall health care costs and delivering improved health outcomes. You may learn more about the ways in which CVS Health is influencing the future of medicine by visiting the website www.cvshealth.com.
Can I use my CVS Caremark card at Walgreens?
The new card will have the CVS Caremark brand, but it may be used to make purchases at any of the participating pharmacies, which include Walgreens, Rite Aid, CVS, Walmart, and Target. On January 1, 2022, how will the change in the pharmacy benefit affect those who are enrolled in Medicare Part D?
Are mail order pharmacies safe?
The Pharmaceutical Care Management Association is a trade group that represents pharmacy benefit managers. They have stated that their members use proprietary software to monitor the weather and map the potential temperatures that a sensitive package may be exposed to while it is being delivered, and that their mail-order pharmacies are safe.
Does Aetna SilverScript cover shingles shot?
The shingles vaccine, in addition to other vaccinations that are commercially available, is covered by Aetna Medicare and SilverScript Part D insurance.
Why did Aetna send me a check?
Aetna investigated after stunning admission
When the subscriber’s provider is not part of the network, certain insurance companies pay the subscriber directly. You have a number of options available to you with regard to the check. You can pay for the services using a personal check, a credit card, or a debit card, and then deposit the money.
Is Adderall covered by Aetna?
Clinical Pharmacy and Therapeutics Committee Bulletins Non-Medicare Prescription Drug Plan Offered by Aetna Agents Used in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD)
| Status | Drug | PR | PR-QL | PR-AL | ST | M EX‡ |
| P | amphetamine/dextroamphetamine | X | ||||
| P | amphetamine/dextroamphetamine sr | X | ||||
| P | clonidine sr | X | X | |||
| P | dexmethylphenidate | X | ||||
| P | dexmethylphenidate sr | X | ||||
| P | dextroamphetamine tab/cap/sol | X | X | |||
| P | metadate ER (methylphenidate SR) | X | ||||
| P | methylin (methylphenidate)-tablets | X | ||||
| P | methylin ER (methylphenidate CR) | X | ||||
| P | methylphenidate | X | ||||
| P | methylphenidate er (methylphenidate sa osm) | X | ||||
| P | methylphenidate SR/ER cap/tab | X | ||||
| P | methamphetamine | X | ||||
| P | Zenzedi™ 5mg, 10mg (dextroamphetamine) | X | ||||
| P | Daytrana® (methylphenidate patch) | X | ||||
| P | Strattera® (atomoxetine) | X | ||||
| P | Vyvanse™ (lisdexamfetamine) | X | ||||
| NP | Adderall® (amphetamine/dextroamphetamine) | X | X | X | X | |
| NP | Dexedrine CR® (dextroamphetamine +) | X | X | X | X | |
| NP | Metadate CD® (methylphenidate CR once-daily +) | X | X | X | X | |
| NP | Ritalin® (methylphenidate +) | X | X | X | X | |
| FE | Adderall XR® (amphetamine/dextroamphetamine SR +) | X | X | X | X | |
| FE | Concerta® (methylphenidate once-daily +) | X | X | X | X | |
| FE | Desoxyn® (methamphetamine +) | X | X | X | X | |
| FE | Focalin™ (dexmethylphenidate +) | X | X | X | X | |
| FE | Focalin XR™ (dexmethylphenidate SR +) | X | X | X | X | |
| FE | Intuniv™ (guanfacine ER +) | X | X | X | X | |
| FE | Kapvay™ (clonidine HCl SR +) | X | X | X | X | |
| FE | Kapvay Therapy Pack™ (clonidine HCl SR +) | X | X | X | X | |
| FE | Methylin® (methylphenidate – chew, solution +) | X | X | X | X | |
| FE | Procentra ® (dextroamphetamine sulfate oral solution +) | X | X | X | X | |
| FE | Quillivant XR™ (methylphenidate susp +) | X | X | X | X | |
| FE | Ritalin LA® (methylphenidate ER +) | X | X | X | X | |
| FE | Ritalin SR® (methylphenidate SR +) | X | X | X | X | |
| FE | Zenzedi™ 2.5mg, 7.5mg (dextroamphetamine +) | X | X | X | X | |
| Over the Counter | ||||||
| ® ™ SM ( ® ™ SM ) ® ™ SM | X | X | X | X | X |
Policy: The Criteria for Precertification Some plans, including those that make use of an open or closed formulary, do not cover certain medications, such as Adderall, Adderall XR, amphetamine/dextroamphetamine, clonidine sr, Concerta, Daytrana, Desoxyn, Dexedrine, dexmethylphenidate, dexmethylphenidate sr, dextroamphetamine, Focalin, Focalin XR, In Aetna considers the following drugs to be medically essential for those members who fulfill the following precertification criteria, even if the precertification standards do not apply to these prescriptions.
- The disorder known as attention deficit hyperactivity disorder (ADHD) OR
- Narcolepsy
AND
- A documented contraindication, intolerance, or allergy, as well as the failure of a 14-day adequate trial of at least three of the following preferred products within the previous year: amphetamine/dextroamphetamine, amphetamine/dextroamphetamine sr, dexmethylphenidate, dexmethylphenidate sr, dextroamphetamine, methamphetamine, methylphenidate, methyl
- The authorisation, which has been in effect for one year, is being renewed by the member.
Members Who Carry Their Own Insurance: A medically-verified diagnosis of one of the following conditions:
- The disorder known as attention deficit hyperactivity disorder (ADHD) OR
- Narcolepsy
Clonidine sr, Intuniv, and Kapvay are all included in the Therapy Pack. For members who are older than 18 years old A diagnosis of attention deficit hyperactivity disorder that is supported by documentation (ADHD) For dextroamphetamine A medically-verified diagnosis of one of the following conditions:
- The disorder known as attention deficit hyperactivity disorder (ADHD) OR
- Narcolepsy
The producers of the stimulant drugs claim that the doses can be increased up to a maximum daily dose, which is shown in the table that follows. According to the following table, the following amounts of each medication will be regarded to be absolutely essential for medical purposes:
| Drug | Maximum Daily Dose | Dosage Strength | Quantity Limits |
| Adderall, amphetamine/ dextroamphet. | 60 mg | 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg, 30 mg | Up to 60 tablets in 30 days |
| Adderall, amphetamine/ dextroamphet. | 60 mg | 20 mg | Up to 90 tablets in 30 days |
| Adderall XR, amphetamine/ dextroamphet. sr | 40 mg | 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg | Up to 30 capsules in 30 days |
| Concerta; methylphenidate er | 72 mg | 18 mg, 27 mg, 54 mg | Up to 30 tablets in 30 days |
| Concerta; methylphenidate er | 72 mg | 36 mg | Up to 60 tablets in 30 days |
| Daytrana | 30 mg | 10 mg/ 9hr 15 mg/ 9hr 20 mg/ 9hr 30 mg/ 9hr | Up to 30 patches in 30 days |
| Desoxyn; methamphetamine | 25 mg | 5 mg | Up to 120 tablets in 30 days |
| dextroamphetamine, Zenzedi | 60 mg | 2.5 mg, 5 mg, 7.5 mg, 10 mg | Up to 120 tablets in 30 days |
| Dexedrine spansule CR; dextroamphetamine CR | 60 mg | 5 mg, 10 mg, 15 mg | Up to 90 capsules in 30 days |
| Focalin; dexmethylphenidate | 20 mg | 2.5 mg, 5 mg, 10 mg | Up to 60 tablets in 30 days |
| Focalin XR; dexmethylphenidate sr | 6 to less than 18 years of age 30 mg | 5 mg, 10 mg, 15mg, 20 mg, 25 mg, 30 mg | Up to 30 capsules in 30 days |
| Focalin XR; dexmethylphenidate sr | greater than or equal to 18 years of age 40 mg | 5mg, 10 mg, 15mg, 20mg, 25 mg, 30 mg, 35mg, 40mg | Up to 30 capsules in 30 days |
| Intuniv | 4 mg | 1 mg, 2 mg, 3 mg, 4 mg | Up to 30 tablets in 30 days |
| Kapvay; clonidine sr | 0.4 mg | 0.1 mg | Up to 120 tablets in 30 days |
| Kapvay Therapy Pack | 0.3 mg | 0.1 mg, 0.2 mg | Up to 1 pack in 30 days |
| Metadate CD | 60 mg | 10 mg, 20mg, 30mg, 40mg, 50mg, 60mg | Up to 30 capsules in 30 days |
| Metadate ER, Methylin, Methylin ER, methylphenidate, methylphen. SR, Ritalin, Ritalin SR | 60 mg | 5 mg, 10 mg, 20 mg | Up to 90 tablets in 30 days |
| Methylin chew tablets | 60 mg | 2.5 mg, 5 mg, 10 mg | Up to 180 tablets in 30 days |
| Methylin solution; methylphenidate solution | 60 mg | 5 mg/5ml | Up to 1800ml in 30 days (60ml/day) |
| Methylin solution; methylphenidate solution | 60 mg | 10 mg/5ml | Up to 900ml in 30 days (30ml/day) |
| Procentra | 60 mg | 5 mg/5ml | Up to 1200ml in 30 days (40ml/day) |
| Quillivant XR | 60 mg | 25 mg/5ml | Up to 360ml in 30 days (12ml/day) |
| Ritalin LA | 60 mg | 10 mg | Up to 30 capsules in 30 days |
| methylphenidate er; Ritalin LA | 60 mg | 20mg, 40mg | Up to 30 capsules in 30 days |
| methylphenidate er; Ritalin LA | 60 mg | 30mg | Up to 60 capsules in 30 days |
| Strattera | 100 mg | 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, | Up to 60 capsules in 30 days |
| Strattera | 100 mg | 80 mg, 100 mg | Up to 30 capsules in 30 days |
| Vyvanse | 70 mg | 20mg; 30mg; 40mg; 50mg; 60mg; 70mg | Up to 30 capsules in 30 days |
Through the Aetna Pharmacy Management Precertification Unit, the member’s treating physician has the ability to submit a request for coverage of increased amounts. It will be determined that members who match any one of the following criteria require additional amounts of the stimulants listed above because they are regarded medically required.
- If the dosage form of the medication is a tablet that can be broken in half, the member is required to take a dose that includes half tablets.
- The physician is now adjusting the member’s dosage (3 month approval limit)
When it comes to amphetamine/dextroamphetamine sr as well as Adderall XR
- Members are required to take the medication twice a day for titration (5mg, 10mg, or 15mg capsules ONLY
- a maximum approved period of three months), OR
- Member requires 40mg total daily dosage (20mg capsule ONLY
- one year approval limit)
Criteria for Step Therapy Steps Adderall, Adderall XR, Concerta, Desoxyn, Dexedrine CR, Focalin, Focalin XR, Intuniv, Kapvay/Therapy Pack, Metadate CD, Methylin (chew, solution), Procentra, Quillivant XR, Ritalin, Ritalin LA, Ritalin SR, and Zenzedi 2.5mg, 7.5mg are examples of medications that For members who satisfy the following step-therapy requirements, Aetna considers these drugs to be medically essential and covers them at no additional cost to the member.
Methylin (chew, solution), Procentra, Quillivant XR, Ritalin, Ritalin LA, Ritalin SR, and Zenzedi 2.5mg, 7.5mg A trial of any three of the following preferred products that was documented to last for a total of 14 days: amphetamine/dextroamphetamine, amphetamine/dextroamphetamine sr, dexmethylphenidate, dexmethylphenidate sr, dextroamphetamine, methamphetamine, methylphenidate, methylphenidate er, methylphenidate sr, Daytran In conjunction with Kapvay and Intuniv/Therapy Pack A trial of any three of the following preferred products for a duration of fourteen days each: clonidine, clonidine sr, guanfacine, amphetamine/dextroamphetamine, amphetamine/dextroamphetamine sr, dexmethylphenidate, dexmethylphenidate sr, dextroamphetamine, methamphetamine, methylphenidate, methylphen If it is medically necessary for a member to be treated initially with a medication that is subject to step-therapy, the member, a person appointed to manage the member’s care, or the member’s treating physician may call the Aetna Pharmacy Management Precertification Unit at 1-800-414-2386 to request coverage as a medical exception.
This can be done by calling the Aetna Pharmacy Management Precertification Unit at the number listed above. (For a list of requirements, see the section III criterion section below.) Medical Exception Criteria Aetna’s Step-Therapy List now includes the prescription stimulants Adderall, Dexedrine CR, Metadate CD, and Ritalin.
As a result, people who are enrolled in prescription drug benefit plans that require step-therapy requirements are not eligible to receive coverage for these medications, unless a medical exemption is granted. Aetna considers the following drugs to be medically required for those of its members who satisfy the following criteria: The following medications are now included on the Aetna Formulary Exclusions and Step-Therapy lists: Adderall XR, Concerta, Desoxyn, Focalin, Focalin XR, Intuniv, Kapvay/Therapy Pack, Methylin (chew, solution), Procentra, Quillivant XR, Ritalin LA/SR, and Zenzedi 2.5mg, 7.5mg.
As Aetna considers the following drugs to be medically required for those of its members who satisfy the following criteria: Methylin (chew, solution), Procentra, Quillivant XR, Ritalin, Ritalin LA, Ritalin SR, and Zenzedi 2.5mg, 7.5mg A medically-verified diagnosis of one of the following conditions:
- The disorder known as attention deficit hyperactivity disorder (ADHD) OR
- Narcolepsy
AND
- A documented contraindication, intolerance, or allergy, as well as the failure of a 14-day adequate trial of at least three of the following preferred products within the previous year: amphetamine/dextroamphetamine, amphetamine/dextroamphetamine sr, dexmethylphenidate, dexmethylphenidate sr, dextroamphetamine, methamphetamine, methylphenidate, methyl
- The authorisation, which has been in effect for one year, is being renewed by the member.
In conjunction with Kapvay and Intuniv/Therapy Pack
- A documented contraindication, intolerance, or allergy, as well as the failure of a 14-day adequate trial of at least three of the following preferred products within the previous year: clonidine, clonidine sr, guanfacine, amphetamine/dextroamphetamine, amphetamine/dextroamphetamine sr, dexmethylphenidate, dexmethylphenidate sr, dextro
- The authorisation, which has been in effect for one year, is being renewed by the member.
– Outpatient Treatment Facilities Are Used The following sources served as inspiration for the aforementioned policy: 1. AHFS Drug Information®, in conjunction with AHFSfirstReleases®. (www. statref.com), Bethesda, Maryland: American Society of Health-System Pharmacists®.
Regularly subject to revision.2. DRUGDEX® System . Thomson Micromedex is headquartered in Greenwood Village, Colorado. Regularly subject to revision.3. Wolters Kluwer Health in St. Louis, Missouri offers an online resource called Drug Facts and Comparisons (www. drugfacts.com). Regularly subject to revision.4.
PDR® Electronic Library™ . Thomson Micromedex is headquartered in Greenwood Village, Colorado. Regularly subject to revision.5. Clinical Pharmacology is next on the list. Gold Standard Inc., headquartered in Tampa, Florida. Regularly subject to revision.6.
Practice Parameter for the Evaluation and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents 2007;46:894-921 in the Journal of the American Academy of Child and Adolescent Psychiatry. Managing stimulant medication for attention-deficit/hyperactivity disorder. Wender, E.H.7.
Pediatr Rev 2001;22(6):183-90.8. Attention-Deficit/Hyperactivity Disorder in Children and Adolescents: Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents, published by the American Academy of Pediatrics.
- Pediatrics 2011;128:1007-22.9.
- The American Academy of Pediatrics (AAP) Attention-Deficit/Hyperactivity Disorder in Children and Adolescents: Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents.
- Additional Information Regarding the Process of Care Appendix 2011 edition of Pediatrics; website address: http://pediatrics.
aappublications. org/content/suppl/2011/10/11/peds.2011-2654. DC1/zpe611117822p. pdf.10. Statement from the Consensus Development Conference held by the National Institutes of Health about the diagnosis and management of attention-deficit/hyperactivity disorder 10.
- (ADHD).2000;39(2):194-7 Journal of the American Academy of Child and Adolescent Psychiatry 11.
- Adult ADHD: Advances in understanding and treatment, published by Manisses Communications Group, Inc.
- Psychopharmacology Update, Volume 13 Number 1 Pages 4-5 12. Kehoe WA.
- The treatment of children who suffer from attention deficit hyperactivity disorder.2001;35:1130–4 of the Ann Pharmacother journal.13.
Searight HR, Burke JM, and Rottnek F. Evaluation and management of adult attention deficit hyperactivity disorder in family practice. The American Family Physician published in 2000; 62:2077-86 and 2091-2. Advances in the pathogenesis and management of mental disorders: implications for internal medicine.14.
- Schweitzer JB, Cummins TK, and Kant CA.
- Medical Clinic 2001:85(3):757-77 in North American.
- Pliszka SR, Greenhill LL, Crismon ML, et al., were the authors of the 15th study.
- Report of the Texas Consensus Conference Panel on Medication Treatment of Attention-Deficit/Hyperactivity Disorder in Childhood The Texas Children’s medication algorithm project The Tactics of the Second Part 2000;39(7):920-7 in the Journal of the American Academy of Child and Adolescent Psychiatry.16.
Swanson, J., et al., “Initiating Concerta (OROS methylphenidate HCl) QD in Children with Attention-Deficit Hyperactivity Disorder,” Journal of Clinical Research, 2000, Volume 3, Number 3, Pages 59-76.17. Schachter HM, Pham B, King J, et al. In the treatment of attention deficit disorder in children and adolescents, how effective is the short-acting version of methylphenidate, and is it safe to use? A meta-analysis.
- CMAJ 2001;165(11):1475-88.18.
- Gonzalez MA, Pentikis HS, Anderl N, et al.
- Bioavailability of methylphenidate derived from two different extended-release formulations 2002;40:175-84 in the International Journal of Clinical Pharmacotherapy.19.
- Dirksen SJH, D’Imperio JM, Birdsall D, Hatch SJ.
- A clinical experience study of Metadate CD after it has been on the market.2002;18:371-80.
Current Medical Research and Opinion.20. Greenhill LL, Findling RL, Swanson JM, and the MPH MR AD/HD Study Group. [cited in:] An investigation on the effects of modified-release methylphenidate on children diagnosed with attention deficit hyperactivity disorder (ADHD), using a double-blind, placebo-controlled design.
Pediatrics.2002;109(3):E39.21. Biederman J, Lopez FA, Boellner SW, Chandler MC. A trial of SL1381 (Adderall XR) in children diagnosed with attention-deficit hyperactivity disorder that used a randomized, double-blind, placebo-controlled, parallel-group design. Pediatrics 2002;110 (2 Pt1):258-66.22. Michelson D, Adler L, Spencer T, and others including themselves.
Two randomized, placebo-controlled investigations of atomoxetine in adults with attention deficit hyperactivity disorder (ADHD). Biol Psychiatry 2003;53:112-20.23. A practice parameter for the utilization of stimulant pharmaceuticals in the treatment of pediatric patients, adolescent patients, and adult patients.2002;41(S2):26S-49S in the Journal of the American Academy of Child and Adolescent Psychiatry.24.
The American Academy of Pediatrics (AAP) Clinical practice guideline for the treatment of attention deficit hyperactivity disorder in school-aged children Pediatrics 2001;108:1033-44 25. Dopheide JA. The importance of medication and other pharmaceutical treatments in the treatment of attention deficit hyperactivity disorder (ADHD).2009;15(S):S141-50 in the American Journal of Managed Care.26.
Minkoff NB. An assessment of the burden of disease as well as potential actions to enhance outcomes is presented about ADHD in managed care.2009;15(S):S151-9 in the American Journal of Managed Care. Copyright and all other rights reserved by Aetna, Inc.
- Aetna creates Pharmacy Clinical Policy Bulletins in order to aid in the administration of plan benefits; however, these bulletins do not constitute offers of coverage nor do they provide medical advice.
- This Clinical Policy Bulletin just provides a broad and general summary of the benefits provided by the plan or program; it is not intended to be interpreted as a contract.
Aetna does not directly deliver patient care, and as a result, the company cannot guarantee any particular results or outcomes. Participating providers are not employees or agents of Aetna or any of its affiliates; rather, they are self-employed professionals working in their own private practices.
The treating providers are the only ones who are accountable for providing members with medical advice and treatment. This Clinical Policy Bulletin may be revised at some point, and as a result, its contents are susceptible to transformation. The 13th of August, 2014 *P = Preferred FE stands for “Formulation Not Included.” NP = Nonpreferred PR = Precertification QL stands for “quantity limits.” AL = Age Limits ST stands for step therapy, MEX stands for medical exception, and RxStep equals rx step.
ETM is an abbreviation for “Essential Therapy Management.” The lists that have been shown thus far are not final. In certain service regions, some programs, such as step-therapy, precertification, and quantity limitations, are not available. In other service areas, these programs are accessible.